Format

Send to

Choose Destination
Cancer Invest. 2014 Nov;32(9):445-50. doi: 10.3109/07357907.2014.958233. Epub 2014 Sep 26.

Docetaxel in castration-resistant prostate cancer: a single-centre experience.

Author information

1
Department of Radiation-Oncology, University of Florence, Florence, Italy,1.

Abstract

We present a single-institution experience reporting the efficacy and safety of docetaxel, administered as first-line chemotherapy, in castration-resistant prostate cancer (CRPC), focusing on patients and treatment parameters. From November 2004 to January 2012, 51 patients received chemotherapy with docetaxel. With a mean follow-up time (from the beginning of CHT) of 1.6 years (range 0.1-5.1 years), 35 patients (68.6%) died for prostate cancer and 48 patients (94.1%) showed progression of the disease. Five factors influenced overall survival: nodal status at diagnosis, neoadjuvant hormonal therapy, number of cycles of docetaxel administered, schedule of docetaxel and ECOG performance status before starting chemotherapy.

KEYWORDS:

Bladder; Chemotherapy; Prostate cancer; Therapy

PMID:
25259606
DOI:
10.3109/07357907.2014.958233
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center